In: Cancer treatment reviews, 2020, vol. 90, p. 11
The DNA damage response (DDR) is a well-coordinated cellular network activated by DNA damage. The unravelling of the key players in DDR, their specific inactivation in different tumor types and the synthesis of specific chemical inhibitors of DDR represent a new hot topic in cancer therapy. In this article, we will review the importance of DDR in lymphoma development and how this can be...
|
In: Current Oncology Reports, 2021, vol. 23, no. 3, p. 10
Purpose of Review Richter syndrome (RS) is an uncommon but aggressive evolution of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). RS is an unmet clinical need in the field of CLL. Recent advances in understanding the biology of this condition provide the rationale for testing new therapeutic concepts in order to improve the outcome of patients developing RS, which is so far...
|
In: Annals of Hematology, 2015, vol. 94, no. 3, p. 421-429
|
In: Cell and Tissue Research, 2015, vol. 359, no. 3, p. 841-851
|
In: Journal of Hematopathology, 2015, vol. 8, no. 1, p. 13-20
|
In: European Journal of Epidemiology, 2015, vol. 30, no. 12, p. 1263-1275
|
In: SLEEP, 2018, vol. 41, no. 9, p. -
|
In: Leukemia, 2021, p. 7 p
The prognostic significance of lymphocyte doubling time (LDT) in chronic lymphocytic leukemia (CLL) was identified when the biology of the disease was poorly understood and therapy was not effective. We assessed the clinical and biological significance of LDT in 848 CLL patients in a real-life setting and the context of new biomarkers and effective therapy. A short LDT (≤12 months) was...
|
In: Blood, 2020, vol. 137, no. 10, p. 1365–1376
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B cell receptor immunoglobulins (BcR IG). Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR IG stereotypy in CLL has important implications for understanding disease...
|
In: Blood, 2020, vol. 135, no. 21, p. 1859–1869
Most patients with chronic lymphocytic leukemia (CLL) are diagnosed with early-stage disease and managed with active surveillance. The individual course of patients with early-stage CLL is heterogeneous, and their probability of needing treatment is hardly anticipated at diagnosis. We aimed at developing an international prognostic score to predict time to first treatment (TTFT) in patients...
|